Crusia 20/ 40/ 60/ 80/ 100 20mg, 40mg, 60mg, 80mg, 100mg SOLUTION FOR INJECTION
PDF Leaflet Revision Date: 19 April 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention and treatment of venous thromboembolism.
Dosage (summary)
40 mg once daily for high-risk surgery; 20 mg once daily for moderate-risk surgery.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use with caution in pregnancy; not known if excreted in breast milk.
Key Drug Interactions
- NSAIDs
- Thrombolytics
- Anticoagulants
Contraindications
- Hypersensitivity to enoxaparin
- Active bleeding
- History of heparin-induced thrombocytopenia
Common side effects
- Haemorrhage
- Thrombocytopenia
- Injection site reactions
Counselling Points
- Monitor for signs of bleeding
- Avoid NSAIDs unless prescribed
- Report any unusual bruising or bleeding
Serious warnings
- Risk of spinal/epidural haematomas
- Increased bleeding risk in renal impairment
Important Disclaimer
The Crusia 20/ 40/ 60/ 80/ 100 20mg, 40mg, 60mg, 80mg, 100mg SOLUTION FOR INJECTION professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
